Business
Cannabics Pharmaceuticals Initiates Penetration for Its Cannabinoid Diagnostic Platform Into European Markets
Cannabics Pharmaceuticals Initiates Penetration for Its Cannabinoid Diagnostic Platform Into European Markets.
About this update from Cnbx Pharmaceuticals Inc.
[{"type":"text","content":"\n\n\n\nCannabics Pharmaceuticals Initiates Penetration for Its Cannabinoid Diagnostic Platform Into European Markets\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nCannabics Pharmaceuticals Initiates Penetration for Its Cannabinoid Diagnostic Platform Into European Markets\nPR Newswire\nTEL AVIV, Israel and BETHESDA, Maryland, July 14, 2020\n\n\n\nTEL AVIV, Israel and BETHESDA, Maryland, July 14, 2020 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that it has initiated activities to penetrate European markets in order to offer a test based on its diagnostic platform to patients who suffer from cancer and are treated with cannabinoids, where regulations permit it.\n\n \n \n \n \n \n \n\n \nIn light of the growing number of European countries that have regulations in place for the medicinal uses of cannabis, combined with the growing number of cancer patients in the continent, the company decided to strategically focus its efforts on making its HTS diagnostic platform available in these territories. \nRegulation in Europe requires clinical trials to be conducted in order to establish the validity of the company's technology. It is the company's intention to conduct further clinical trials to accomplish this milestone. \nThe company's diagnostic platform utilizes its High Throughput Screening (HTS) facility, located in Israel. It is designed for cancer patients who seek the optimal cannabinoid composition.\nIn this test, cancer cells, in the form of a biopsy, are derived from a patient, and are then screened against dozens of cannabinoid compositions, which stem from what is available in the patients' respective territory. Once exposed to the cannabinoid compositions, the cancer cells are monitored for apoptotic and necrotic effects. The results are then reported back to the patients and their practitioners, assisting them with making cannabinoid-based therapy decisions for optimal outcomes. \nAccording to a report issued by the World Health ...